ImmunityBio, Inc. — Form 10-Q
Filed August 4, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 48/100
What the filing says
ImmunityBio entered into a Development and Supply Agreement with Japan BCG Laboratory (JBL) effective May 14, 2026, for exclusive manufacturing and supply of an intravesical BCG pharmaceutical product for urothelial cancers in the U.S. Territory. JBL will manufacture the product at cGMP-compliant facilities; ImmunityBio holds exclusive commercialization rights, is the sole Marketing Authorization Holder in the U.S., and commits to purchase a minimum of 2 batches annually post-FDA approval. The agreement runs for 10 years from FDA approval (thereafter renewable or terminable); specific pricing, batch sizes, and other financial terms are redacted. ImmunityBio may terminate for convenience with 12 months' notice.
Why this rating
Meaningful supply deal for BCG product development; establishes manufacturing secured for U.S. market. Moderate relative to ~$690M market cap—early-stage, contingent on FDA approval (not yet obtained), and financial terms redacted. Positive for pipeline but execution risk remains.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.